Gemtuzumab ozogamicin (marketed by Wyeth as Mylotarg) is a drug-linked
monoclonal antibody (an antibody-drug conjugate) that was used to treat acute ...
This page contains brief information about gemtuzumab ozogamicin and a
collection of links to more information about the use of this drug, research results,
Mylotarg is the trade name for gemtuzumab ozogamicin. In some cases, health
care professionals may use the trade name mylotarg when referring to the ...
Mylotarg® (gemtuzumab ozogamicin for Injection) is a chemotherapy agent
composed of a recombinant humanized IgG4, kappa antibody conjugated with a
Jun 13, 2013 ... Gemtuzumab ozogamicin (GO) consists of a humanized anti-CD33 monoclonal
antibody conjugated with calicheamicin, a potent antitumor ...
Mylotarg (gemtuzumab ozogamicin): Market Withdrawal. Audience: Oncology,
Hematology. [Posted 06/21/2010]. ISSUE: FDA notified healthcare professionals
Nov 10, 2012 ... On May 17, 2000, the US Food and Drug Administration (FDA) granted
accelerated approval for the use of gemtuzumab ozogamicin (GO) in ...
PURPOSE: Gemtuzumab ozogamicin (Mylotarg; Wyeth Laboratories,
Philadelphia, PA) consists of a semisynthetic derivative of calicheamicin, a
Bioconjug Chem. 2002 Jan-Feb;13(1):47-58. Gemtuzumab ozogamicin, a potent
and selective anti-CD33 antibody-calicheamicin conjugate for treatment of ...
Information about the monoclonal antibody gemtuzumab (Mylotarg®), which is
mainly used as part of research trials to treat some types of acute myeloid ...